Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

We recently compiled a list of the 10 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a ...

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM) ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that ...

Under the agreement, UCB gains a non-exclusive license to leverage XtalFold for the discovery and engineering of biologics.

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug discovery, today announced a license ...

Drug discovery is a key area for AI, given the speed at which models trained on massive datasets can tackle a variety of tasks. Last year, Nvidia said it was doubling down on AI-powered drug discovery ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put ...

The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug ... workflow for monoclonal antibody discovery ...